Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer.
<h4>Background</h4>In 2018, the treatment options for unresectable stage III non-small cell lung cancer (NSCLC) changed with durvalumab, an immune checkpoint inhibitor (ICI), which was approved for consolidation therapy following concurrent chemoradiotherapy (cCRT) without disease progre...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0314156&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!